These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 27591327)

  • 21. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
    BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
    Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
    Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment for lupus nephritis.
    Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
    Basu B; Roy B; Babu BG
    Pediatr Nephrol; 2017 Jun; 32(6):1013-1021. PubMed ID: 28191596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
    Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS
    Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
    Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate mofetil in lupus glomerulonephritis.
    Mok CC; Lai KN
    Am J Kidney Dis; 2002 Sep; 40(3):447-57. PubMed ID: 12200794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Kotb A; Wells GA
    Syst Rev; 2016 Sep; 5(1):155. PubMed ID: 27619512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
    Contreras G; Tozman E; Nahar N; Metz D
    Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
    Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.
    Kamanamool N; McEvoy M; Attia J; Ingsathit A; Ngamjanyaporn P; Thakkinstian A
    Medicine (Baltimore); 2010 Jul; 89(4):227-235. PubMed ID: 20616662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D; Rodrigues M; da Silva JAP; Inês L
    Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
    Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E;
    Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.
    Lenz O; Fornoni A; Contreras G
    Drugs; 2005; 65(17):2429-36. PubMed ID: 16296869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.
    Baskin E; Ozen S; Cakar N; Bayrakci US; Demirkaya E; Bakkaloglu A
    Pediatr Nephrol; 2010 Jan; 25(1):111-7. PubMed ID: 19727839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pharmacoeconomic study comparing the use of mycophenolate mofetil or cyclophosphamide as induction therapy in lupus nephritis patients in Egypt.
    Khattab NM; Abbassi M; A Raafat H; Farid S
    Lupus; 2022 Apr; 31(4):505-516. PubMed ID: 35254887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
    Gul H; Mushtaq MS; Salim B; Samreen S; Nasim A; Khan M
    J Ayub Med Coll Abbottabad; 2020; 32(4):454-458. PubMed ID: 33225643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
    Koo HS; Kim YC; Lee SW; Kim DK; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ
    Lupus; 2011 Nov; 20(13):1442-9. PubMed ID: 21951944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?
    Hogan J; Schwenk MH; Radhakrishnan J
    Kidney Int; 2012 Dec; 82(12):1256-60. PubMed ID: 22648298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
    Chbihi M; Eveillard LA; Riller Q; Brousse R; Berthaud R; Quartier P; Salomon R; Charbit M; Avramescu M; Biebuyck N; Dehoux L; Garcelon N; Duong-Van-Huyen JP; Bader-Meunier B; Boyer O
    J Nephrol; 2023 Apr; 36(3):829-839. PubMed ID: 36208405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.